Immunovant (NASDAQ: IMVT) stock: the official figures
Immunovant (Immunovant, Inc.) is listed on Nasdaq under the ticker IMVT and belongs to the health care sector. In fiscal 2026 it reported a net loss of $505.6m, according to the annual accounts it filed with the regulator. Its fiscal year ends on 31 March.
Identifiers for Immunovant: SEC CIK 1764013.
Fiscal 2026 figures
| Item | 2026 | 2025 | Change |
|---|---|---|---|
| Operating profit | −$505.4m | −$412.9m | — |
| Net profit | −$505.6m | −$413.8m | — |
| Earnings per share | −$2.77 | −$2.73 | — |
| Total assets | $957.0m | $776.2m | +23.3% |
| Equity | $852.6m | $707.4m | +20.5% |
| Cash | $902.1m | $714.0m | +26.4% |
| Operating cash flow | −$407.3m | −$375.9m | — |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
8 fiscal years
| Fiscal year | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|
| 2026 | −$505.4m | −$505.6m | −$2.77 | Annual report |
| 2025 | −$412.9m | −$413.8m | −$2.73 | Annual report |
| 2024 | −$258.8m | −$259.3m | −$1.88 | Annual report |
| 2023 | −$211.0m | −$211.0m | −$1.71 | Annual report |
| 2022 | −$156.8m | −$156.7m | −$1.43 | Annual report |
| 2021 | −$107.8m | −$107.4m | −$1.22 | Annual report |
| 2020 | −$65.7m | −$66.4m | — | Annual report |
| 2019 | −$28.6m | −$28.6m | — | Annual report |
The full income statement, balance sheet and cash flow statement are in the annual accounts of Immunovant. Purchases and sales by its executives and directors are in insider transactions.
Frequently asked questions about Immunovant
- How much did Immunovant earn in fiscal 2026?
- Immunovant reported a net loss of $505.6m for fiscal 2026. The year before it reported a net loss of $413.8m.
- What are the earnings per share of Immunovant?
- They were −$2.77 in fiscal 2026, compared with −$2.73 the year before.
- Where is Immunovant listed?
- Immunovant is listed on Nasdaq under the ticker IMVT and belongs to the health care sector.
- Where do the figures for Immunovant come from?
- From the annual report (Form 10-K) that Immunovant files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the annual report (Form 10-K) that Immunovant files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.